We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?
Read MoreHide Full Article
CorMedix (CRMD - Free Report) shares rallied 19.5% in the last trading session to close at $12.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.1% loss over the past four weeks.
CorMedix’s stock surge was observed after the company announced strong preliminary third-quarter 2025 results and raised full-year guidance. Preliminary pro forma revenue in the reported quarter exceeded $125 million, driven by robust DefenCath sales exceeding $85 million and growing utilization across its customer base. The company also raised its full-year 2025 pro forma net revenue guidance to at least $375 million, up from the prior $325–$350 million range, signaling stronger-than-expected top-line momentum. Positive investor sentiment was likely reinforced by projected third-quarter adjusted EBITDA of $70 million, anticipated $30 million in operational synergies from the Melinta integration, and strategic pipeline progress, including the ongoing late-stage study of Rezzayo for prophylaxis of invasive fungal infections. Coupled with a projected year-end cash balance of approximately $100 million, these factors suggest improved profitability, growth potential, and financial flexibility, which contributed to the notable share price gain.
This pharmaceutical and medical device company is expected to post quarterly earnings of $0.48 per share in its upcoming report, which represents a year-over-year change of +1060%. Revenues are expected to be $69.55 million, up 506.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For CorMedix, the consensus EPS estimate for the quarter has been revised 55.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CRMD going forward to see if this recent jump can turn into more strength down the road.
CorMedix is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Legend Biotech Corporation Sponsored ADR (LEGN - Free Report) , finished the last trading session 3% higher at $32.91. LEGN has returned -6% over the past month.
For Legend Biotech, the consensus EPS estimate for the upcoming report has changed +16.7% over the past month to -$0.08. This represents a change of +76.5% from what the company reported a year ago. Legend Biotech currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains?
CorMedix (CRMD - Free Report) shares rallied 19.5% in the last trading session to close at $12.16. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.1% loss over the past four weeks.
CorMedix’s stock surge was observed after the company announced strong preliminary third-quarter 2025 results and raised full-year guidance. Preliminary pro forma revenue in the reported quarter exceeded $125 million, driven by robust DefenCath sales exceeding $85 million and growing utilization across its customer base. The company also raised its full-year 2025 pro forma net revenue guidance to at least $375 million, up from the prior $325–$350 million range, signaling stronger-than-expected top-line momentum. Positive investor sentiment was likely reinforced by projected third-quarter adjusted EBITDA of $70 million, anticipated $30 million in operational synergies from the Melinta integration, and strategic pipeline progress, including the ongoing late-stage study of Rezzayo for prophylaxis of invasive fungal infections. Coupled with a projected year-end cash balance of approximately $100 million, these factors suggest improved profitability, growth potential, and financial flexibility, which contributed to the notable share price gain.
This pharmaceutical and medical device company is expected to post quarterly earnings of $0.48 per share in its upcoming report, which represents a year-over-year change of +1060%. Revenues are expected to be $69.55 million, up 506.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For CorMedix, the consensus EPS estimate for the quarter has been revised 55.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CRMD going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
CorMedix is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Legend Biotech Corporation Sponsored ADR (LEGN - Free Report) , finished the last trading session 3% higher at $32.91. LEGN has returned -6% over the past month.
For Legend Biotech, the consensus EPS estimate for the upcoming report has changed +16.7% over the past month to -$0.08. This represents a change of +76.5% from what the company reported a year ago. Legend Biotech currently has a Zacks Rank of #3 (Hold).